Search

Updated: Jan 27

Reglagene placed second in the RESI Innovation Challenge during JP Morgan Week in San Francisco (January 2020). Hosted by Life Science Nation, RESI conferences bring together global early-stage companies across Biotech, Medtech, Diagnostics & Digital Health with life science strategic partners, family offices, venture funds, and angel investors.


The RESI Innovation Challenge featured 30 early-stage life science companies from around the world that are selected by Life Science Nation’s internal scientific review board to be part of the RESI Innovation Challenge, presenting their technologies in an exhibition-style format throughout the full-day conference.


Attendees at the RESI conference are provided with "RESI Bucks" to “invest” in the most promising companies during the full day event. The capital invested is then tallied up and the top three winners receive prizes and are featured in the RESI newsletter recap that goes out to Life Science Nation’s 23,000 newsletter readership to meet with some of the top innovators in the field and invest their “RESI Cash.”



This is the second win for Reglagene in the last month. The company was announced as a winner of the Fall 2019 Arizona Innovation Challenge on December 11, 2019. A business plan competition for promising early-stage companies in high-growth industries awards $1.5 million twice a year. The winners receive as much as $150,000 each, released in phases as each company reaches certain milestones, as well as the benefit of participating in the Arizona Commerce Authority’s Venture Ready Accelerator, which connects companies with serial entrepreneurs, high-level executives, and subject matter experts. The program is designed to help startups refine their business plan, improve go-to-market strategies, and increase investor readiness.

Updated: Jan 27

TUCSON, AZ (December 11, 2019) — The Arizona Commerce Authority (ACA) announced today that Reglagene is among 10 awardees in the Fall 2019 round of the Arizona Innovation Challenge. The business plan competition—one of the largest in the country—is designed to advance innovation and technology commercialization opportunities in Arizona by helping early-stage ventures scale.


“Congratulations to our Fall 2019 awardees!”, said Sandra Watson, President and CEO of the Arizona Commerce Authority. “Each of these companies is advancing exciting innovations in digital health, wearables, fintech, SaaS, and more. We could not be more proud to help them scale and achieve success in Arizona.”


Companies chosen to join the Arizona Innovation Challenge portfolio will participate in the ACA's Venture Ready Accelerator, which connects companies with serial entrepreneurs, high-level executives, and subject matter experts. Venture Ready helps startups refine their business plans, improve go-to-market execution strategies, and increase investor readiness. Participants will complete a series of panels and workshops within the subsequent 12 months of the award. About Reglagene

Reglagene Holding Inc. is a therapeutics discovery and development company. They leverage technology developed at the University of Arizona to discover and develop new medicines. Visit reglagene.com for more information.



About the Arizona Commerce Authority The Arizona Commerce Authority (ACA) is the state’s leading economic development organization, with a streamlined mission to grow and strengthen Arizona’s economy. The ACA uses a three-pronged approach to advance the overall economy: attract, expand, create—attract out-of-state companies to establish operations in Arizona; work with existing companies to expand their business in Arizona and beyond; and help entrepreneurs create new Arizona businesses in targeted industries. For more information, please visit azcommerce.com and follow the ACA on Twitter @azcommerce.

Updated: Feb 27, 2020

Reglagene is delighted to add Sharon Ayd, PhD, MBA to its Board of Directors. In Dr. Ayd’s 30-year career, she has gained experience commercializing pharmaceuticals from discovery to clinical evaluation, expanded core businesses, and transformed pharmaceutical business operations. Her career began as a research scientist for Baxter International. She went on to serve in a variety of executive positions at companies including Apotex Inc., Hospira (now Pfizer), Fresenius-Kabi, Transcend Therapeutics, Advanced Life Sciences, and Pinnacle Biologics. Dr. Ayd is an industry expert in regulatory strategy and pharmaceutical operations. She has led the regulatory affairs activity for many due diligence projects, resulting in product licensing, mergers and acquisitions, and divestitures. Under her leadership, ~100 drug application approvals (original and supplements) have been obtained. Dr. Ayd holds an MBA from Lewis University and a PhD from the University of Illinois at Chicago in Biopharmaceutical Sciences, and she is an alumnus of Women In Bio’s inaugural class in its Boardroom Ready program, a foundational resource to prepare executive women for service on corporate boards.